Gemcitabine News
SciClone Initiates Phase 2 Trial of RP101 in Late-Stage Pancreatic Cancer Patients
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the first patient has been dosed in its phase 2 clinical trial using RP101, a nucleoside analog which may act to enhance the beneficial effect of chemotherapy,...
Gemcitabine/Bevacizumab Plus Radiation Appear Active in Patients With Pancreatic Cancer: Presented at ASCO-GI
Doctors said that the combination of gemcitabine and bevacizumab along with radiation in the treatment of patients with pancreatic cancer does not appear to create any major safety issues, even when some of the patients have...
Conformal Radiation With Gemcitabine and Erlotinib Feasible in Unresected Pancreatic Cancer Patients: Presented at ASCO-GI
Patients with pancreatic cancer appear to tolerate the standard chemotherapy agent gemcitabine in combination with both the targeted agent erlotinib and with conformal radiation procedures.
Shilpa cancer drugs get Korean nod
Raichur, Karnataka-based Shilpa Medicare has got South Korean Food and Drug Administration (KFDA) approval for Ambroxol HCL and Gemcitabine HCL after submitting drug master files (DMFs). Both are cancer midications.
Gemzar® plus Second Chemotherapy Agent Provides Small Survival Benefits in Advanced Pancreatic Cancer
According to results recently published in the journal Drugs and Aging, the combination of Gemzar® (gemcitabine) with a second chemotherapy agent provides small but significant improvements in survival compared with Gemzar only...